Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III RCT Comparing Low Dose Immunotherapy (Nivolumab) Combined With Standard Chemotherapy vs Standard Chemotherapy as First-line Treatment in Patients With Locally Advanced or Metastatic NSCLC

NCT07050043 is registered in ClinicalTrials.gov with Dr Arvindran A/L Alaga as lead sponsor.

NCT NCT07050043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07050043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III RCT Comparing Low Dose Immunotherapy (Nivolumab) Combined With Standard Chemotherapy vs Standard Chemotherapy as First-line Treatment in Patients With Locally Advanced or Metastatic NSCLC
Lead sponsor
Dr Arvindran A/L Alaga
Phase
Phase 3
Overall status
Recruiting
Start date
May 19, 2025
Completion date
December 31, 2030
Enrollment
123 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

first line therapy, locally advanced/metastatic nsclc, nsclc (non-small cell lung carcinoma)